As a new pharmaceutical technology, mRNA has made breakthroughs in the treatment of infectious diseases and tumors in a short time. At present, one of the major obstacles in clinical mRNA technology is to determine how to deliver mRNA to a specific target cell and protect it from degradation, so the ideal delivery vector must be safe, stable, and organ specific.